Blood Transfusion in Hip Replacement Surgery: Current Practices and Risk Reduction

Allogeneic blood transfusion rates in primary total hip arthroplasty (THA) have dropped from ~20–30% to 5–10% or lower with modern protocols.

Multimodal Blood Conservation Strategies

1. Preoperative Optimization

• Screen for anemia (CBC, ferritin, B12, folate) 4+ weeks before surgery.
• Treat iron deficiency: oral iron (3–4 weeks) or IV iron (faster repletion).
• Erythropoiesis-stimulating agents (ESAs) in select cases (e.g., Jehovah's Witnesses, severe anemia).

2. Minimally Invasive Surgical Techniques

• Anterior, anterolateral, or muscle-sparing approaches reduce tissue trauma and blood loss.
• Meticulous hemostasis, tranexamic acid (TXA) topical/intravenous.

3. Intraoperative Blood Management

• Tranexamic acid (TXA): 10–20 mg/kg IV pre-incision + 1 g topical; reduces blood loss 30–50% without increasing thromboembolism.
• Controlled hypotension: Target MAP 50–60 mmHg (if tolerated).
• Cell salvage (autotransfusion): Collect, wash, reinfuse lost blood—especially useful in revision THA.

4. Autologous Pre-donation

Rarely used now; logistically complex, risk of wastage, and preoperative anemia from donation. Not routinely recommended.

5. Restrictive Transfusion Thresholds

• Guidelines (AABB, ASA): Transfuse at Hb <7–8 g/dL in stable patients; <8 g/dL with cardiac disease.
• Symptom-driven (not number-driven) decisions.

Risk Factors for Transfusion

• Preoperative anemia (Hb <13 g/dL men, <12 g/dL women)
• Age >75, low BMI, female sex
• Revision, bilateral, or complex primary THA
• Anticoagulant/antiplatelet use
• Comorbidities (CKD, liver disease, CAD)

With optimization, most patients undergo THA without transfusion. Discuss your personal risk and blood management plan with your surgical team.